Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc. (CYDY) is a clinical-stage biotechnology and oncology company whose news flow centers on the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Company announcements frequently highlight progress in solid tumor oncology, particularly metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC), as well as broader CCR5-related research.
Investors following CYDY news can expect updates on clinical trial milestones, including Phase 2 studies in mCRC and planned Phase 2 proof-of-concept and combination trials in mTNBC. Press releases and shareholder letters describe retrospective survival analyses, PD-L1 upregulation findings, and the company’s “prime and pair” strategy that combines leronlimab with immune checkpoint inhibitors. Conference-related news often covers poster and oral presentations at major oncology meetings such as the San Antonio Breast Cancer Symposium, European Society for Medical Oncology events, and AACR specialty conferences.
CytoDyn’s news stream also includes corporate and regulatory developments. Recent items have addressed the resolution of government investigations, an agreement in principle to settle a securities class action lawsuit, and stockholder approval of amendments to increase authorized common shares. Financing updates, such as the Standby Equity Purchase Agreement with Yorkville, provide insight into how the company plans to support its clinical programs.
In addition, CytoDyn issues periodic letters to shareholders that summarize operational rebuilding, regulatory interactions, and collaborations with academic centers in areas like glioblastoma, Alzheimer’s disease, and HIV cure research. For readers tracking CYDY, this news page offers a consolidated view of scientific data releases, trial progress, financing arrangements, and governance actions that shape the company’s development trajectory.
CytoDyn Inc. (OTCQB: CYDY) has announced the initiation of its Biologics License Application (BLA) resubmission for HIV, guided by the FDA. The current phase involves submitting non-clinical and CMC sections, with the clinical section expected in Q1 2022. CEO Nader Pourhassan expressed optimism over progress, noting patients from the CD02 trial have achieved prolonged viral load suppression. The company is also preparing to file for expanded access to leronlimab for urgent cases. CytoDyn is focused on addressing previous BLA issues and exploring further clinical trials for various conditions.
CytoDyn Inc. (OTCQB: CYDY) announced it submitted a Breakthrough Therapy designation application to the FDA for leronlimab as a treatment for metastatic triple-negative breast cancer (mTNBC). This application is based on positive findings from a study involving 28 patients who had failed multiple treatments. Key results show a median overall survival of 12+ months for those on higher doses of leronlimab, exceeding traditional treatment options. The CEO expressed hope for improved patient outcomes and anticipates FDA feedback before year-end.
CytoDyn Inc. (OTCQB: CYDY) announced updated results from its ongoing cancer study using leronlimab for treating 28 patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC). The updated analysis shows a 3600% increase in 12-month Overall Survival (OS) and a 580% increase in 12-month Progression Free Survival (PFS). CEO Nader Pourhassan stated that they are preparing a Breakthrough Therapy application to the FDA. Leronlimab holds Fast Track designation for HIV and mTNBC, with several ongoing clinical trials targeting various conditions.
CytoDyn Inc. (OTCQB: CYDY) announced preliminary results from its Phase 2 trial of leronlimab for treating nonalcoholic steatohepatitis (NASH). Findings from five patients indicated reductions in fatty deposits by up to 45% and fibrosis by 10% in four out of five patients. The trial aims to show if leronlimab can inhibit liver fibrosis in NASH. The company plans to submit a Breakthrough Therapy designation application and expects more data in December. Currently, there are no FDA-approved treatments for NASH, affecting 3-12% of U.S. adults.
CytoDyn Inc. (OTCQB: CYDY) announced that its 2021 Annual Meeting of Shareholders was convened and subsequently adjourned due to the absence of a quorum, attributed to the activist group led by Paul Rosenbaum and Bruce Patterson failing to submit proxies. The meeting is rescheduled for November 24, 2021, to allow further proxy solicitation. Shareholders are urged to vote using the provided BLUE proxy card. CytoDyn continues its efforts to advance clinical trials for leronlimab, targeting various therapeutic uses including HIV and cancer.
CytoDyn Inc. (OTCQB: CYDY) has announced the FDA's acceptance of its revised "Rolling Review" timeline for the resubmission of its Biologics License Application (BLA) for leronlimab, targeted at highly treatment-experienced HIV patients. The Company expects to resubmit the non-clinical and CMC sections in November 2021, with the clinical section anticipated in early 2022. Leronlimab aims to serve multiple indications, including HIV and metastatic triple-negative breast cancer, having shown significant promise in clinical trials.
CytoDyn Inc. (OTCQB: CYDY) has initiated its pivotal Phase 3 trial (CD16) for critically ill COVID-19 patients in Brazil, treating the first patient recently. An interim analysis will assess outcomes after 127 patients are enrolled. The trial focuses on patients needing mechanical ventilation and utilizes leronlimab, a CCR5 antagonist. Compared to prior trials, new dosing methods via IV could enhance drug absorption. The company aims to file for Emergency Use Authorization after promising initial results from prior studies indicate significant survival benefits.
CytoDyn Inc. (OTCQB: CYDY) will host a webcast for the investment community on October 26, 2021, led by key executives, including CEO Nader Pourhassan. The 30-minute presentation will be followed by 60 minutes of Q&A. CytoDyn seeks investor participation ahead of its Annual Meeting set for October 28, 2021, urging votes using the blue proxy card. The company continues its development of leronlimab, which has received FDA Fast Track designation for HIV and metastatic cancer treatment. Leronlimab has shown promise in clinical trials, including significant efficacy in HIV and cancer models.
CytoDyn Inc. (OTCQB: CYDY) announced that the Delaware Court of Chancery has denied an activist group's motion to delay the company's annual meeting scheduled for October 28, 2021. The court emphasized that denying the meeting would harm the company, citing that necessary steps for the meeting had been completed. The company urges shareholders to vote using the BLUE proxy card, disregarding any votes for the activist group's nominees. Only shareholders of record as of September 1, 2021 are eligible to vote.
CytoDyn Inc. (OTCQB: CYDY) announced that shareholders will receive proxy materials this week for the 2021 Annual Meeting on October 28, 2021. Shareholders are urged to vote their shares immediately to ensure their votes count. Following a Delaware Court of Chancery ruling on October 13, the company will disregard director nominations from an activist group. Only votes from shareholders recorded as of September 1, 2021 will be considered valid.